Research
Awards Grant
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
A5272/A5280 Supplemental Funds from Adult Clinical Trials Group
A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"
A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV
AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support
AIDS Clinical Trials Group Network (ACTG)
AIDS Clinical Trials Group: Protocol Funds
AIDS Clinical Trials Group: Protocol Funds FTE Funding
Aids Clinical Trial Group: ACTG
Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee
Autophagy-Lysosome Pathway Function in HIV: Effects of Antiretroviral Therapy and Relevance to Neurocognitive Status
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop De Novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection (CTOT-02/CCTPT-02)
Cardiovascular Disease Risk in HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants
Cardiovascular Inflammation Reduction Trial (CIRT)
Cardiovascular Inflammation Reduction Trial (CIRT): A Randomized Double-Blind Placebo-Controlled, Event-Driven Trial of Weekly Low-Dose Methotrexate (LDM) in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients
Clinical Implications, Genomics, and Transcriptomics of Mucus Plugging in Smokers
Computed Tomographic Characterization of Subjects Enrolled in the STATCOPE Investigation
Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)
ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy
Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314
HPS 3/TIMI 55-Reveal (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification)
HPS 3/TIMI 55: REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification)
HPS-4/TIMI 65/ORION-4: A double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People with Atherosclerotic Cardiovascular Disease
Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)
Kit Inhibition in Asthma (KIA)
Long Term Oxygen Treatment Trial (LOTT) Pharmacogenomics Ancillary Study
PEGASUS:A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction
PREPARE - Person Empowered Asthma Relief-fka Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations
Pharmacogenomics of Inhaled Corticosteroids to Reduce COPD Exacerbations
SAVOR: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial To Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stoke in Patients with Type 2 Diabetes
SOLID TIMI 52: Stabilization of Plaques Using Darapladib--A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - SAVOR-TIMI53. A Multicentre, Randomised, Double-Blind, Placbeo-Controlled Phase IV Trial to Evaluate the Effects of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infraction or Ischaemic Stroke in Patients with Type 2 Diabetes
Treatments Against RA and Effect of FDG PET-CT: The TARGET Trial
Virology Speciality Laboratory
